Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on May 6, 2010, covering events occurring on May 2 and May 4, 2010. The company is a Delaware corporation headquartered in Annapolis, Maryland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Executive Appointment: On May 2, 2010, the Board appointed Eric I. Richman as Interim Chief Executive Officer. Mr. Richman had previously served as President and Chief Operating Officer since March 25, 2010, and joined the company in 2003 as Senior Vice President of Business Development and Strategic Planning.
- Board Resignation: On May 4, 2010, David P. Wright resigned from the Board of Directors.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, specific risks, contingencies, or unusual items. The document is limited to reporting the departure and appointment of officers and directors.
Investor Verification Checklist
- Verify the effective date of Eric I. Richman's appointment as Interim CEO and his prior tenure as President and COO.
- Confirm the resignation date of David P. Wright from the Board of Directors.
- Review subsequent filings to determine if the Interim CEO role was made permanent or if a permanent CEO was appointed.
- Check for any related proxy statements or 10-Q filings to understand the financial context surrounding these leadership changes.